2022 World Conference on Lung Cancer (ePosters)-EP08.01-072. Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy

EP08.01-072. Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy

Back to course

Pdf Summary

Researchers have evaluated the clinical significance of the Patras Immunotherapy Score (PIOS) formula in patients with advanced non-small cell lung cancer (NSCLC) who were treated with a combination of immunotherapy and chemotherapy. The PIOS formula takes into account performance status, body mass index, age, and line of treatment. A total of 159 patients who received immunotherapy/chemotherapy and 444 patients who received chemotherapy alone were included in the study.<br /><br />The results showed that a higher PIOS score was associated with longer progression-free survival (PFS) in patients receiving the combination therapy. The association remained significant even after adjusting for PD-L1 expression. In addition, the PIOS score was also related to overall survival (OS), with patients in the favorable group having a significantly longer median OS compared to the unfavorable group.<br /><br />Importantly, the study confirmed the prognostic value and specificity of the PIOS model in NSCLC patients receiving immunotherapy/chemotherapy combination. However, no prognostic significance for the PIOS was observed in the group of patients treated with chemotherapy alone.<br /><br />These findings suggest that the PIOS formula can be a useful tool in predicting outcomes and guiding treatment decisions for patients with advanced NSCLC receiving combination immunotherapy and chemotherapy. Further research and validation of the PIOS formula in larger patient cohorts are warranted to confirm its clinical utility.<br /><br />For more information, contact fodimitrakopoulos@upatras.gr.

Asset Subtitle

Petros Christopoulos

Meta Tag

Speaker Petros Christopoulos

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Patras Immunotherapy Score

PIOS formula

non-small cell lung cancer

advanced NSCLC

immunotherapy

chemotherapy

performance status

body mass index

age

line of treatment